analysts and calls -- CSFB Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : analysts and calls -- CSFB

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	2/6/2003 1:26:28 PM
From: Icebrg	Read Replies (1) of 14

NEW YORK, Feb 6 (Reuters) - Credit Suisse First Boston said on Thursday it had started coverage of several biotechnology companies. Analyst Mark Augustine started ICOS Corp. (ICOS - News) and Myriad Genetics Inc. (MYGN - News) with "outperform" ratings and Human Genome Sciences Inc. (HGSI - News) and Millenium Pharmaceuticals Inc. (MLNM - News) as "neutral. No other details were immediately available. ICOS closed on the Nasdaq at $23.08 on Wednesday, Myriad at $11.04, Human Genome at $6.34, and Millenium at $6.48.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next